(Q46755861)

English

A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis (English)

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

author name string

Bo Liu

1

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

Dongxia Ye

2

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

Xinxin Song

3

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

Xinhua Zhao

4

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

Linan Yi

5

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

Jietao Song

6

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

Zhiyuan Zhang

7

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

Qingzheng Zhao

8

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

language of work or name

0 references

publication date

22 January 2008

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

26

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

1387-1396

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

10

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Chapter 2: The burden of HPV-related cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Mycobacterial heat shock proteins as vaccines - a model of facilitated antigen presentation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Calreticulin: one protein, one gene, many functions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Functional specialization of calreticulin domains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Efficient expression of modified human papillomavirus 16 e6/e7 fusion protein and the antitumor efficacy in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Models for studying angiogenesis in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of anti-angiogenic agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Priming of T cells by exogenous antigen cross-presented on MHC class I molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Exiting the outside world for cross-presentation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Mechanisms of normal and tumor-derived angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Control of cancers by combining antiangiogenesis and cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

The immune response to mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively disregulated in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.034

7 January 2021

Identifiers

10.1016/J.VACCINE.2007.12.034

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18272260

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46755861&oldid=2129921497"